LUPIN

BSE: 500257 06 Oct 2025

Healthcare

₹ 1978.2

Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.

LUPIN

BSE: 500257 06 Oct 2025

Healthcare

₹ 1978.2

Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.

Book Value

377.0

Dividend Yield

0.63%

Debt to Equity

0.32

Stock P/E

23.7

Market Cap

87,688 Cr

LUPIN - Share Price & Details

Market Cap

₹87,688

High /Low

2,403 / 1,774

Stock P/E

23.7

Book Value

₹377.0

Dividend Yield

0.63

ROCE

21.3

ROE

₹20.6

Face Value

2.0

PEG Ratio

0.4

EVEBITDA

₹15.1

Debt

5,448

CMP / FCF

58.3

Debt to equity

₹0.32

NP Ann

3,306

High price all time

2,403

Piotroski score

₹6.0

Graham Number

829.0

No. Eq. Shares

45.7

Net CF

₹560

Net profit

3,722

Price to book value

5.09

Interest Coverage

₹14.9

Low price all time

52.5

Industry PE

33.0

Reserves

₹17,112

Free Cash Flow

₹1,347

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
21 Aug 2025	Mirae Asset Sharekhan	Buy	₹1,961.9	₹2,400	21.5%	moneycontrol	View
07 Aug 2025	Prabhudas Lilladher	Buy	₹1,851.6	₹2,400	23.4%	moneycontrol	View
07 Aug 2025	ICICI Securities	Hold	₹1,851.6	₹1,950	0.2%	moneycontrol	View
07 Aug 2025	Emkay Global Financial Services	Buy	₹1,946.3	₹2,500	30.3%	moneycontrol	View
30 May 2025	ICICI Securities	Hold	₹1,964.8	₹2,110	5.7%	moneycontrol	View
28 May 2025	Motilal Oswal	Hold	₹1,964.8	₹2,200	10.2%	moneycontrol	View
15 May 2025	Motilal Oswal	Hold	₹2,071.4	₹2,200	11.1%	moneycontrol	View
13 Feb 2025	Prabhudas Lilladher	Buy	₹2,024.9	₹2,420	17.7%	moneycontrol	View
13 Feb 2025	KRChoksey	Buy	₹2,055.65	₹2,472	25.4%	moneycontrol	View
30 Dec 2024	Emkay Global Financial Services	Buy	₹2,309.65	₹2,750	16.7%	moneycontrol	View
12 Nov 2024	KRChoksey	Buy	₹2,088.05	₹2,472	18.4%	moneycontrol	View
10 Nov 2024	Emkay Global Financial Services	Buy	₹2,104.3	₹2,750	31.7%	moneycontrol	View
10 Nov 2024	Prabhudas Lilladher	Buy	₹2,104.3	₹2,420	15.9%	moneycontrol	View
08 Nov 2024	Sharekhan	Buy	₹2,104.3	₹2,400	15%	moneycontrol	View
08 Aug 2024	KRChoksey	Buy	₹2,051.25	₹2,443	17.3%	moneycontrol	View
08 Aug 2024	Prabhudas Lilladher	—	₹2,051.25	₹2,300	10.4%	moneycontrol	View
07 Aug 2024	Sharekhan	Buy	₹1,992.7	₹2,400	15.2%	moneycontrol	View
07 Aug 2024	Motilal Oswal	Hold	₹1,992.7	₹2,050	-1.5%	moneycontrol	View
10 Jul 2024	ICICI Securities	Sell	₹1,826.85	₹1,615	-22.4%	moneycontrol	View
09 May 2024	Motilal Oswal	Hold	₹1,584.25	₹1,550	-25.5%	moneycontrol	View
07 May 2024	Sharekhan	Buy	₹1,610.55	₹1,868	-10.2%	moneycontrol	View
07 May 2024	Prabhudas Lilladher	Hold	₹1,610.55	₹1,675	-19.5%	moneycontrol	View
15 Apr 2024	Sharekhan	Buy	₹1,608.35	₹1,868	-10.2%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
LUPIN LTD.	57627.3	21280.7	57085.9	46.48	87,688	23.7
FORTIS HEALTHCARE LTD.	4730.4	518.8	4330.3	0.69	70419	76.5
Alkem Laboratories Limited	24887.5	6561.6	23721.7	52.04	64960	28.6

Peer Comparison Chart

About LUPIN

Lupin Ltd, with Security Code 500257, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Cipla, Biocon, Lupin, Other Pharma Stocks Under Pressure Post Trumps 100% Tariff

(26 Sep 2025)

Nifty Pharma index declined 2.67% intraday on Friday after US President Donald Trump announced a 100% tariff on the sector with an exception...

Lupin shares surge over 2% on tentative USFDA approval for HIV-treatment tablets

(26 Sep 2025)

Lupin share price: The USFDA has approved the pharmaceutical major's abbreviated new drug application for Bictegravir, Emtricitabine,...

Lupin receives tentative approval from US FDA for Biktarvy tablets

(26 Sep 2025)

Lupin announced that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New...

Lupin shares rise 2% on US FDA approval for HIV drug; stock up 12 times in 15 sessions

(26 Sep 2025)

By 11:33 am, the stock was trading 1.19 per cent higher at Rs 2014.90, giving the company a market capitalisation of Rs 92031 crore.

Stocks to watch: Tata Steel, Glenmark Pharma, Lupin, Polycab India among shares in focus today

(25 Sep 2025)

The company has infused ₹4,054.66 crore into its overseas subsidiary, T Steel Holdings Pte. Ltd (TSHP), through the acquisition of 457.7...

Stocks to Watch, September 25: Shipping stocks, Glenmark Pharma, Shriram Finance, Muthoot Finance, Lupin, Polycab

(25 Sep 2025)

Stocks to Watch: Shares of companies such as Shipping Corporation of India (SCI), GE Shipping, and Mazagon Dock, among others, will be in...

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	2,836.3	3,495.6	3,659.2	4,115.8	3,395.9	4,167.6	4,106.2	4,208.0	4,485.7	5,708.6
Expenses	2,574.1	2,790.6	2,824.0	2,898.4	2,695.5	2,968.0	2,991.5	2,797.0	2,739.5	2,979.0
Operating Profit	262.2	705.0	835.2	1,217.3	700.4	1,199.7	1,114.8	1,411.1	1,746.2	2,729.6
OPM %	9.24%	20.17%	22.83%	29.58%	20.62%	28.79%	27.15%	33.53%	38.93%	47.82%
Other Income	55.3	27.7	25.6	23.2	31.3	38.2	32.6	-21.9	48.8	54.1
Interest	29.4	16.2	15.3	11.4	13.5	13.6	17.6	19.6	33.9	18.9
Depreciation	146.2	140.1	149.5	145.2	290.0	141.4	145.8	152.5	208.0	176.7
Profit before tax	141.8	576.5	696.0	1,084.0	428.2	1,082.9	984.1	1,294.3	1,553.2	2,588.2
Tax %	-16.1%	-17.3%	-21.2%	-15.5%	-10.3%	-17.9%	-17.9%	-19.1%	-16.9%	17.8%
Net Profit	119.0	477.0	548.6	916.4	384.1	889.2	807.8	984.7	1,291.4	2,128.1
EPS in Rs	2.59	10.44	12.01	20.05	8.4	19.44	17.66	21.52	0	46.48

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	4,322.2	4,430.1	4,814.1	5,038.6	5,197.4	4,960.8	5,600.3	5,672.7	5,767.7	5,667.1
Expenses	3,789.6	3,852.3	3,957.8	4,120.8	4,159.5	3,963.9	4,359.4	4,332.4	4,411.8	4,345.9
Operating Profit	532.7	577.8	856.3	917.8	1,037.9	996.9	1,241.0	1,340.4	1,355.9	1,321.2
OPM %	12.32%	13.04%	17.79%	18.21%	19.97%	20.09%	22.16%	23.63%	23.51%	23.31%
Other Income	18.0	37.3	22.8	40.4	29.4	29.3	67.8	42.3	53.7	57.0
Interest	84.1	92.6	85.7	80.6	74.0	71.3	68.0	70.9	66.9	89.1
Depreciation	220.4	264.0	234.7	247.9	257.2	457.1	247.7	256.9	271.5	393.2
Profit before tax	246.1	258.5	558.8	629.7	736.1	497.7	993.0	1,054.9	1,071.3	895.9
Tax %	-36%	-6.2%	-18.9%	-21.3%	-15.9%	-26%	-18.9%	-18.5%	-19.8%	-12.7%
Net Profit	157.7	242.4	453.3	495.3	618.7	368.2	805.5	859.5	858.9	782.4
EPS in Rs	3.36	5.16	9.9	10.72	13.41	7.86	17.52	18.64	18.69	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	6%
5 Years:	9%
3 Years:	13%
TTM:	16%

Compounded Profit Growth
10 Years:	5%
5 Years:	28%
3 Years:	173%
TTM:	75%

Stock Price CAGR
10 Years:	1%
5 Years:	17%
3 Years:	49%
1 Year:	21%

Compounded Sales Growth
10 Years:	6%
5 Years:	8%
3 Years:	11%
TTM:	13%

Compounded Profit Growth
10 Years:	3%
5 Years:	55%
3 Years:	60%
TTM:	73%

Stock Price CAGR
10 Years:	1%
5 Years:	17%
3 Years:	49%
1 Year:	21%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

LUPIN

LUPIN

LUPIN - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About LUPIN

Order Book

Latest News

Cipla, Biocon, Lupin, Other Pharma Stocks Under Pressure Post Trumps 100% Tariff

Lupin shares surge over 2% on tentative USFDA approval for HIV-treatment tablets

Lupin receives tentative approval from US FDA for Biktarvy tablets

Lupin shares rise 2% on US FDA approval for HIV drug; stock up 12 times in 15 sessions

Stocks to watch: Tata Steel, Glenmark Pharma, Lupin, Polycab India among shares in focus today

Stocks to Watch, September 25: Shipping stocks, Glenmark Pharma, Shriram Finance, Muthoot Finance, Lupin, Polycab

Stocks To Watch Today: Tata Steel, Dalmia Bharat, Lupin, Max Financial And More

Lupin shares gain 2% after USFDA approval for HIV drug

Stocks To Watch Today, Sep 25: BEL, L&T, Bajaj Electricals, Suzlon, Lupin, NTPC Green Energy and others

Lupin gets FDA nod for HIV drug; to be manufactured in Nagpur unit

Lupin gets tentative nod from USFDA for generic HIV treatment drug

Lupin gets USFDA tentative nod for HIV drug generic, to be made in Nagpur

Stocks to Watch: Polycab, Tata Steel, Lupin, Piramal Enterprises and more

Lupin gets tentative USFDA nod for HIV drug

Lupin's Pune Biotech facility undergoes USFDA pre-approval inspection

U.S. FDA issues 4 observations to Lupin’s Pune Biotech facility

Lupin gets 4 USFDA observations for Pune Biotech facility

Lupins Pune Facility Gets Four Observations After US FDA Inspection

Lupin gets US FDA Approval for Generic Lenalidomide Capsules

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Lupin Gets US FDA Approval For Generic Lenalidomide Capsules

Lupin shares fall as firm gets six USFDA observations at Nagpur injectable facility; details here

Lupin shares in focus after USFDA issues six observations for Nagpur facility

Stocks To Watch Today: Lupin, Tech Mahindra, Pidilite, BEL, Jindal Steel

Midcap Losers: Lupin, Ola Electric stocks among top losers on Nifty Midcap 150 index today

Lupin slides after receiving six observations from USFDA for Nagpur facility

Lupin Shares Slump as Nagpur Facility Gets 6 Observations

Lupin Shares Decline After USFDA Issues Six Observations for Nagpur Plant

Lupin shares slip over 1% after USFDA issues six observations at Nagpur plant

Lupin Ltd. - Positive Breakout: These 9 stocks close cross above their 200 DMAs

Lupin, Astra Microwave among top analyst bets; check target, stop-loss

Lupin Limited's (NSE:LUPIN) market cap touched ₹933b last week, benefiting both private companies who own 46% as well as institutions

Lupin shares climb after Investec upgrade on reasonable valuations; raises target

Lupin Ltd. Shows Strong Momentum Amid Broader Market Gains and Positive Sentiment

Top midcap gainers: NLC India, Lupin, Supreme Industries stocks lead on Nifty Midcap 150 index today

Lupin Shares Jump Over 3% As Investec Hikes Target Price, Upgrades To Buy

Lupin Shares Surge 3% After Investec's Upgrade to 'Buy'

Lupin Ltd spurts 0.51%, gains for fifth straight session

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform

Biotecnika Times Newsletter 09.09.2025 – Freshers Jobs at Lupin, Sun Pharma, WFH Jobs at Premier Research (US-Based Company), TERI, TMC, RGCB Hiring + Admissions Open at Dr. B. Lal Institute of Biotechnology

Now Sun Pharma, Lupin work on anti-obesity pill to cut costs, address jab aversion | Company Business News

Sun Pharma, Lupin push for affordable anti-obesity pills in India - Mint

Stock Alert: Adani Power, Lupin, Dr Reddy's Laboratories, Imagicaaworld Entertainment, Kaynes Technology India

Lupin gets 2 USFDA observations for Aurangabad facility

lupin has received approval from usfda for its anda for risperidone

Lupin Ltd. Shows Signs of Trend Reversal Amid Market Dynamics in Pharmaceuticals Sector

Lupin Secures USFDA Approval for Innovative Injectable Schizophrenia Treatment

Lupin gets USFDA nod for generic risperidone extended-release injectable suspension

Lupin Gets USFDA Nod for Generic Risperidone Extended-Release Injectable Suspension

Lupin Shares End 3% Higher on USFDA Nod for Schizophrenia, Bipolar Disorder Drug

Lupin Gains on USFDA Nod for Risperidone Injectable

Lupin receives USFDA nod for injectable used to treat Schizophrenia and bipolar disorder

Lupin receives US FDA approval for Risperidone long-acting Injectable

Lupin share price rises 3% as USFDA okays schizophrenia drug; details

Lupin receives USFDA approval for generic risperidone extended-release injectable suspension, stock ends over 3% higher

Lupin shares rise 2.20%; among top gainers on Nifty Midcap 150

Lupin Gets Expert Committee Nod To Conduct Phase I Trial of Certolizumab Pegol, IGRA TB Test Made...

LUPIN Outlook for the Week

Sun Pharma, Lupin, Dr Reddy’s Drop Up To 4% As Trump’s Pharma Shock Spooks Investors

Catalyst Pharmaceuticals Announces Settlement Agreement with Lupin to Resolve FIRDAPSE Patent Litigation

12-Year Patent Protection: Catalyst Pharma Locks FIRDAPSE Exclusivity Until 2035 in Lupin Settlement

Catalyst Pharma Settles Patent Dispute with Lupin

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Catalyst Pharmaceuticals and SERB Settle Patent Litigation with Lupin Regarding FIRDAPSE®

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE®

Nifty in short-term uptrend mode, buy UNO Minda, Lupin shares: Rupak De

'Buy' UNO Minda, Lupin shares; 'Sell' Axis Bank: LKP Securities' analyst

Lupin, Natco Launch Bosentan Tablets in US With 180-Day Exclusivity

Natco Pharma Launches Generic Drug in US